IL263800A - Multimeric gitr binding molecules and uses thereof - Google Patents

Multimeric gitr binding molecules and uses thereof

Info

Publication number
IL263800A
IL263800A IL263800A IL26380018A IL263800A IL 263800 A IL263800 A IL 263800A IL 263800 A IL263800 A IL 263800A IL 26380018 A IL26380018 A IL 26380018A IL 263800 A IL263800 A IL 263800A
Authority
IL
Israel
Prior art keywords
multimeric
binding molecules
gitr binding
gitr
molecules
Prior art date
Application number
IL263800A
Other languages
English (en)
Hebrew (he)
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of IL263800A publication Critical patent/IL263800A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL263800A 2016-07-20 2018-12-18 Multimeric gitr binding molecules and uses thereof IL263800A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364762P 2016-07-20 2016-07-20
PCT/US2017/043166 WO2018017889A1 (en) 2016-07-20 2017-07-20 Multimeric gitr binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
IL263800A true IL263800A (en) 2019-02-28

Family

ID=60992910

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263800A IL263800A (en) 2016-07-20 2018-12-18 Multimeric gitr binding molecules and uses thereof

Country Status (9)

Country Link
US (2) US20190330360A1 (OSRAM)
EP (1) EP3487299A4 (OSRAM)
JP (1) JP2019528683A (OSRAM)
CN (1) CN109561681A (OSRAM)
AU (1) AU2017300647A1 (OSRAM)
CA (1) CA3030659A1 (OSRAM)
IL (1) IL263800A (OSRAM)
MX (1) MX2019000799A (OSRAM)
WO (1) WO2018017889A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
BR112016018313A8 (pt) 2014-02-10 2018-06-12 Igm Biosciences Inc Moléculas de ligação multiespecíficas iga
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
SI3265575T1 (sl) 2015-03-04 2021-08-31 Igm Biosciences, Inc. Vezne molekule CD20 in njihove uporabe
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
ES2996834T3 (en) 2015-09-30 2025-02-13 Igm Biosciences Inc Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
CA3021669A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
JP2022505663A (ja) * 2018-10-23 2022-01-14 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
CN115485299A (zh) * 2020-04-22 2022-12-16 Igm生物科学股份有限公司 Pd-1激动剂多聚结合分子
US20240002526A1 (en) * 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN113151186B (zh) * 2021-02-04 2022-02-18 上海交通大学 抗人cd271的单克隆抗体及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3148579T3 (pl) * 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
KR102435324B1 (ko) * 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
EP3356401B1 (en) * 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain

Also Published As

Publication number Publication date
EP3487299A1 (en) 2019-05-29
EP3487299A4 (en) 2020-03-11
CN109561681A (zh) 2019-04-02
MX2019000799A (es) 2019-06-03
AU2017300647A1 (en) 2019-02-07
JP2019528683A (ja) 2019-10-17
CA3030659A1 (en) 2018-01-25
US20190330360A1 (en) 2019-10-31
WO2018017889A1 (en) 2018-01-25
US20220177595A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
IL263800A (en) Multimeric gitr binding molecules and uses thereof
IL263799A (en) Multimeric ox40 binding molecules and uses thereof
IL269534A (en) Chimeric molecules and their uses
IL272463B2 (en) Nucleic acid molecules and their uses
IL254223A (en) CD20 binding compounds and their uses
IL266464A (en) Binding of specific molecules to asct2 and their use
ZA201706875B (en) De novo binding domain containing polypeptides and uses thereof
IL251891A0 (en) CD73-specific binding molecules and uses thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
ZA201803841B (en) Binding molecules specific for asct2 and uses thereof
IL273641B (en) Specific binding molecules for il-21 and uses thereof
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
GB201503812D0 (en) Antibody molecules and uses thereof
HK40002713A (en) Multimeric gitr binding molecules and uses thereof
HK40002716A (zh) 多聚ox40结合分子及其用途
GB201612534D0 (en) Antibodies and related molecules and uses thereof
GB201604378D0 (en) Antibodies and related molecules and uses thereof
HK1241931A1 (zh) Cd20結合分子及其用途